Aytu BioPharma (NASDAQ: AYTU) CEO Josh Disbrow on Exxua, ADHD Portfolio and Key Milestones for 2026

In this interview, Josh Disbrow, CEO of Aytu BioPharma, Inc. (NASDAQ: AYTU), shares updates on the company's recent developments, including the launch of Exxua, a depression treatment, and discusses future growth catalysts.

Chapters

00:00 Introduction to Aytu BioPharma, Inc.
01:50 Company Overview and Recent Developments
04:10 Key Highlights and Product Launch
05:07 Future Catalysts and Growth Strategy

Aytu BioPharma, Inc. will be presenting at the upcoming Planet MicroCap Las Vegas 2026 powered by MicroCapClub. Register to attend here: https://www.meetmax.com/sched/event_130817/conference_home.html

For more information about Aytu BioPharma, Inc., please visit: https://aytubio.com/

The interview may contain forward looking statements about Aytu BioPharma, Inc. See Aytu BioPharma, Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.

About Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.

Planet Microcap hosts the highest quality in-person microcap events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow.; visit https://planetmicrocap.com/ to learn more about our Las Vegas and Toronto events.

This presentation is for informational purposes only and should not be construed as a recommendation to purchase or sell any security referenced herein. Planet MicroCap Holdings LLC and MicroCapClub LLC (collectively, “we” or “our”) are not licensed brokers nor registered investment advisors. We, our partners, contractors, members, subscribers, guests, or affiliates may or may not hold positions in one or more of the securities mentioned in this presentation and may trade in such securities at any time. We may have received cash compensation from one or more participants for presenting at past, present, or future events. We recommend you consult a licensed investment adviser, broker, or legal counsel before purchasing or selling any securities referenced in this presentation.

Видео Aytu BioPharma (NASDAQ: AYTU) CEO Josh Disbrow on Exxua, ADHD Portfolio and Key Milestones for 2026 канала Planet MicroCap